Possesses both local anesthetic and antiarrhythmic properties (class 1C agent). Elevates the ventricular fibrillation threshold and protects against ouabain-induced arrhythmias in animal models. Its mechamism of action is primarly inhibition of sodium channels in a voltage- and frequency-dependent fashion. Also inhibits the microsomal Na+,K+-ATPase in a concentration-dependent manner (IC50=33.5µM) . Reduces neuronal death in cellular models of hypoxic injury when combined with a glutamate receptor antagonist and blocks aconitine-induced mortality in a rat model (ED50=30mg/kg).
Product Details
Alternative Name: | N-(4-Chlorophenyl)-N-[1-(1-isopropyl)-4-piperidinyl]phenylacetamide . HCl |
|
Formula: | C22H27ClN2O . HCl |
|
MW: | 370.9 . 36.5 |
|
CAS: | 58934-46-6 |
|
Purity: | ≥98% (TLC) |
|
Appearance: | White solid. |
|
Solubility: | Soluble in water (>30mg/ml), DMSO (>25mg/ml) or 100% ethanol (>25mg/ml). |
|
Shipping: | Ambient Temperature |
|
Long Term Storage: | Ambient |
|
Use/Stability: | Store, as supplied, at room temperature for up to 1 year. Store solutions at -20°C for up to 3 months. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Sodium channel blockers reduce oxygen-glucose deprivation-induced cortical neuronal injury when combined with glutamate receptor antagonists: J.J. Lynch, 3rd, et al.; J. Pharmacol. Exp. Ther.
273, 554 (1995),
Abstract;
Influence of lorcainide on microsomal Na+, K(+)-ATPase in guinea-pig isolated heart preparations: A.A. Almotrefi & N. Dzimiri; Br. J. Pharmacol.
102, 530 (1991),
Abstract;
Antiarrhythmic drugs and the cardiac sodium channel: current models: R.S. Sheldon, et al.; Clin. Chem.
35, 748 (1989),
Abstract;
Inhibition of aconitine-induced mortality in the conscious rat: a screening test for antiarrhythmic drugs: B. Gutierrez, et al.; Methods Find. Exp. Clin. Pharmacol.
9, 307 (1987),
Abstract;